Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.92 CAD | +0.61% | -1.80% | +24.56% |
Apr. 08 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
Mar. 14 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.56% | 113M | |
+12.06% | 69.11B | |
+5.16% | 25.91B | |
+4.48% | 8.01B | |
-4.25% | 7.91B | |
-23.97% | 7.27B | |
-0.67% | 4.51B | |
+20.68% | 4.48B | |
-4.23% | 3.95B | |
-3.99% | 3.79B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics : Q2 Net Loss Narrows YoY to US$0.07 Per Share; Revenue Up to Nearly US$15 Million